Market Research Reports and Industry Reports

Hepatocellular Carcinoma - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Hepatocellular Carcinoma - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 79, 51, 3, 72, 10 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 11, 7, 1, 26 and 2 molecules, respectively.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 8
Hepatocellular Carcinoma - Overview 9
Hepatocellular Carcinoma - Therapeutics Development 10
Hepatocellular Carcinoma - Therapeutics Assessment 42
Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 64
Hepatocellular Carcinoma - Drug Profiles 125
Hepatocellular Carcinoma - Dormant Projects 1068
Hepatocellular Carcinoma - Discontinued Products 1076
Hepatocellular Carcinoma - Product Development Milestones 1079
Appendix 1092

List Of Tables

List of Tables
Number of Products under Development for Hepatocellular Carcinoma, H2 2017 37
Number of Products under Development by Companies, H2 2017 39
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 40
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 41
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 42
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 43
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 44
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 45
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 46
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 47
Number of Products under Development by Universities/Institutes, H2 2017 48
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 50
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 51
Products under Development by Companies, H2 2017 52
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 53
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 54
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 55
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 56
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 57
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 58
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 59
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 60
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 61
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 62
Products under Development by Companies, H2 2017 (Contd..11), H2 2017 63
Products under Development by Companies, H2 2017 (Contd..12), H2 2017 64
Products under Development by Companies, H2 2017 (Contd..13), H2 2017 65
Products under Development by Universities/Institutes, H2 2017 66
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 67
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 68
Number of Products by Stage and Target, H2 2017 70
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 71
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 72
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 73
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 74
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 75
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 76
Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 77
Number of Products by Stage and Mechanism of Action, H2 2017 79
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 80
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 81
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 82
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 83
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 84
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 85
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 86
Number of Products by Stage and Route of Administration, H2 2017 88
Number of Products by Stage and Molecule Type, H2 2017 90
Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H2 2017 91
Hepatocellular Carcinoma - Pipeline by Abivax SA, H2 2017 91
Hepatocellular Carcinoma - Pipeline by ACEA Biosciences Inc, H2 2017 92
Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2017 92
Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H2 2017 93
Hepatocellular Carcinoma - Pipeline by Amgen Inc, H2 2017 93
Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H2 2017 94
Hepatocellular Carcinoma - Pipeline by ArQule Inc, H2 2017 94
Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H2 2017 94
Hepatocellular Carcinoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 95
Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H2 2017 95
Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017 96
Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2017 96
Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H2 2017 97
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017 97
Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017 98
Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H2 2017 98
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H2 2017 99
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017 99
Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H2 2017 99
Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Co, H2 2017 100
Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H2 2017 101
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H2 2017 101
Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H2 2017 101
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2017 102
Hepatocellular Carcinoma - Pipeline by Celgene Corp, H2 2017 102
Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H2 2017 103
Hepatocellular Carcinoma - Pipeline by Cellivery Therapeutics Inc, H2 2017 103
Hepatocellular Carcinoma - Pipeline by Celsion Corp, H2 2017 104
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H2 2017 104
Hepatocellular Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H2 2017 104
Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 105
Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H2 2017 105
Hepatocellular Carcinoma - Pipeline by Curevac AG, H2 2017 106
Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H2 2017 106
Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2017 107
Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H2 2017 107
Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H2 2017 107
Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H2 2017 108
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Co, H2 2017 109
Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H2 2017 109
Hepatocellular Carcinoma - Pipeline by Epizyme Inc, H2 2017 110
Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H2 2017 110
Hepatocellular Carcinoma - Pipeline by Eureka Therapeutics Inc, H2 2017 110
Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H2 2017 111
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 111
Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H2 2017 112
Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H2 2017 112
Hepatocellular Carcinoma - Pipeline by Genelux Corp, H2 2017 112
Hepatocellular Carcinoma - Pipeline by Genentech Inc, H2 2017 113
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2017 113
Hepatocellular Carcinoma - Pipeline by Genosco Inc, H2 2017 114
Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H2 2017 114
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2017 115
Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H2 2017 115
Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H2 2017 116
Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H2 2017 116
Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H2 2017 117
Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H2 2017 117
Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H2 2017 117
Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2017 118
Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H2 2017 118
Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H2 2017 119
Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H2 2017 119
Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H2 2017 119
Hepatocellular Carcinoma - Pipeline by Incyte Corp, H2 2017 120
Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H2 2017 120
Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2017 121
Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H2 2017 121
Hepatocellular Carcinoma - Pipeline by Ipsen SA, H2 2017 122
Hepatocellular Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 122
Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H2 2017 123
Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H2 2017 123
Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H2 2017 123
Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H2 2017 124
Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H2 2017 124
Hepatocellular Carcinoma - Pipeline by Kowa Co Ltd, H2 2017 125
Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H2 2017 125
Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 126
Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H2 2017 126
Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H2 2017 127
Hepatocellular Carcinoma - Pipeline by Medivir AB, H2 2017 127
Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H2 2017 128
Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2017 128
Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 129
Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H2 2017 129
Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 129
Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H2 2017 130
Hepatocellular Carcinoma - Pipeline by Molecular Templates Inc, H2 2017 130
Hepatocellular Carcinoma - Pipeline by MTG Biotherapeutics Inc, H2 2017 130
Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H2 2017 131
Hepatocellular Carcinoma - Pipeline by NeuroVive Pharmaceutical AB, H2 2017 131
Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H2 2017 132
Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2017 132
Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H2 2017 133
Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H2 2017 133
Hepatocellular Carcinoma - Pipeline by Omeros Corp, H2 2017 134
Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H2 2017 134
Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H2 2017 135
Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 135
Hepatocellular Carcinoma - Pipeline by OSE Immunotherapeutics, H2 2017 136
Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H2 2017 136
Hepatocellular Carcinoma - Pipeline by PepVax Inc, H2 2017 136
Hepatocellular Carcinoma - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017 137
Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H2 2017 138
Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H2 2017 138
Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H2 2017 139
Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H2 2017 139
Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH (Inactive), H2 2017 139
Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 140
Hepatocellular Carcinoma - Pipeline by Q BioMed Inc, H2 2017 140
Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H2 2017 141
Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H2 2017 141
Hepatocellular Carcinoma - Pipeline by Samumed LLC, H2 2017 141
Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H2 2017 142
Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H2 2017 142
Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2017 143
Hepatocellular Carcinoma - Pipeline by Simcere Pharmaceutical Group, H2 2017 143
Hepatocellular Carcinoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 144
Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H2 2017 144
Hepatocellular Carcinoma - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 145
Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H2 2017 145
Hepatocellular Carcinoma - Pipeline by tella Inc, H2 2017 145
Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017 146
Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H2 2017 146
Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2017 146
Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2017 147
Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H2 2017 147
Hepatocellular Carcinoma - Pipeline by Twoxar Inc, H2 2017 148
Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H2 2017 148
Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H2 2017 148
Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2017 149
Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H2 2017 149
Hepatocellular Carcinoma - Pipeline by VG Life Sciences Inc, H2 2017 149
Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H2 2017 150
Hepatocellular Carcinoma - Pipeline by Xspray Pharma AB, H2 2017 150
Hepatocellular Carcinoma - Pipeline by Yooyoung Pharm Co Ltd, H2 2017 150
Hepatocellular Carcinoma - Pipeline by Zhejiang Conba Pharmaceutical Co Ltd, H2 2017 151
Hepatocellular Carcinoma - Dormant Projects, H2 2017 1095
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..1), H2 2017 1096
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..2), H2 2017 1097
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..3), H2 2017 1098
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..4), H2 2017 1099
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..5), H2 2017 1100
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..6), H2 2017 1101
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..7), H2 2017 1102
Hepatocellular Carcinoma - Discontinued Products, H2 2017 1103
Hepatocellular Carcinoma - Discontinued Products, H2 2017 (Contd..1), H2 2017 1104
Hepatocellular Carcinoma - Discontinued Products, H2 2017 (Contd..2), H2 2017 1105

Hepatocellular Carcinoma - Pipeline Review, H2 2017

Hepatocellular Carcinoma - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides an overview of the Hepatocellular Carcinoma

USD 2500View Report

2017-2022 Metastatic Hepatocellular Carcinoma (HCC) Report on Global and United States Market, Status and Forecast, by Players, Types and Applications

This report studies the Metastatic Hepatocellular Carcinoma (HCC) market status and outlook of global and major regions, from angles of players, regions, product and end Application/industries; this report analyzes the

USD 3600View Report

2017-2022 Metastatic Hepatocellular Carcinoma (HCC) Report on Global and United States Market, Status and Forecast, by Players, Types and Applications

This report studies the Metastatic Hepatocellular Carcinoma (HCC) market status and outlook of global and major regions, from angles of players, regions, product and end Application/industries; this report analyzes the

USD 3600View Report

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Insight, 2017

DelveInsights, Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Recurrent Head And Neck Cancer Squamous Cell

USD 1250View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 2500
  • Site Licence    USD 5000
  • Enterprise Wide Licence    USD 7500
$ 2500

Reports Details

Published Date : Nov 2017
No. of Pages :1120
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube